PPARG and cancer: Several cancers have shown reduced growth with PPARγ activation with the TZD troglitazone such as in carcinomas of the breast, kidney, liver, colon, pancreas, and prostate [34–39] as well as in non-small-cell lung cancer [40] and ACTH-secreting pituitary adenomas [41].